Viking Therapeutics Recent VK2809 Update, Analyst Review and Target

NEW YORK, NY / ACCESSWIRE / June 6, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, therapies for metabolic and endocrine disorders.

On June 5th, the company announced that enrolment had been completed in the company’s ongoing Phase 2 clinical trial of VK2809.

On May 30, the company shares closed at $4.97 and as of June 5th, were trading at $10.12 per share.

Read more about VK2809 and get an analyst review and target price here READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/viking-therapeutics-2/

In vivo studies have shown that treatment with VK2809 leads to significant improvement in markers related to NASH development, severity, and progression. In addition, prior clinical data in subjects with mild hypercholesterolemia have demonstrated that treatment with VK2809 results in significant reductions in LDL cholesterol, triglycerides and atherogenic proteins.

Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

Get details and updates on the VKTX pipeline and a Q1 financial review READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/viking-therapeutics-2/

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 501827